Accelerate Diagnostics Valuation
| AXDX Stock | USD 1.18 0.01 0.84% |
Today, the firm appears to be overvalued. Accelerate Diagnostics shows a prevailing Real Value of $1.08 per share. The current price of the firm is $1.18. Our model approximates the value of Accelerate Diagnostics from analyzing the firm fundamentals such as return on asset of -0.66, and Current Valuation of 67.61 M as well as examining its technical indicators and probability of bankruptcy. Key fundamental drivers impacting Accelerate Diagnostics' valuation include:
Overvalued
Today
Please note that Accelerate Diagnostics' price fluctuation is extremely dangerous at this time. Calculation of the real value of Accelerate Diagnostics is based on 3 months time horizon. Increasing Accelerate Diagnostics' time horizon generally increases the accuracy of value calculation and significantly improves the predictive power of the methodology used.
Since Accelerate Diagnostics is currently traded on the exchange, buyers and sellers on that exchange determine the market value of Accelerate Stock. However, Accelerate Diagnostics' intrinsic value may or may not be the same as its current market price, in which case there is an opportunity to profit from the mispricing, assuming the market price will eventually merge with its intrinsic value. | Historical | Market 1.18 | Real 1.08 | Target 1.5 | Hype 1.18 | Naive 1.18 |
The intrinsic value of Accelerate Diagnostics' stock can be calculated using various methods such as discounted cash flow analysis, price-to-earnings ratio, or price-to-book ratio. That value may differ from its current market price, which is determined by supply and demand factors such as investor sentiment, market trends, news, and other external factors that may influence Accelerate Diagnostics' stock price. It is important to note that the real value of any stock may change over time based on changes in the company's performance.
Estimating the potential upside or downside of Accelerate Diagnostics helps investors to forecast how Accelerate stock's addition to their portfolios will impact the overall performance. We also use other valuation drivers to help us estimate the true value of Accelerate Diagnostics more accurately as focusing exclusively on Accelerate Diagnostics' fundamentals will not take into account other important factors: Traditionally, analysts and sophisticated investors use multiple methods for valuing a cash-flow-generating entity or its stock. For example, some money managers use Accelerate Diagnostics' intrinsic value based on its ongoing forecasts of Accelerate Diagnostics' financial statements. In contrast, other private, professional wealth advisors use a multiplier approach by looking to relative value analysis against Accelerate Diagnostics' closest peers.
Accelerate Diagnostics Cash |
|
Accelerate Valuation Trend
Analysing the historical paterns of Accelerate Diagnostics' enterprise value and its market capitalization is a good way to estimate and gauge the value of Accelerate Diagnostics over time and is usually enough for investors to make rational market timing decisions.
Accelerate Diagnostics Total Value Analysis
Accelerate Diagnostics is presently forecasted to have valuation of 67.61 M with market capitalization of 28.55 M, debt of 39.22 M, and cash on hands of 36.77 M. Please note that valuation may be misleading and is a subject to auditing or accounting errors. We encourage investors to vigilantly validate all of the Accelerate Diagnostics fundamentals before making equity appraisal based on enterprise value of the company| Takeover Price | Market Cap | Debt Obligations | Cash |
67.61 M | 28.55 M | 39.22 M | 36.77 M |
Accelerate Diagnostics Investor Information
About 38.0% of the company shares are held by company insiders. The company recorded a loss per share of 2.59. Accelerate Diagnostics had not issued any dividends in recent years. The entity had 1:10 split on the 12th of July 2023. Based on the key indicators related to Accelerate Diagnostics' liquidity, profitability, solvency, and operating efficiency, Accelerate Diagnostics may be sliding down financialy. It has an above-average probability of going through some form of financial hardship next quarter.Accelerate Diagnostics Asset Utilization
The asset utilization indicator refers to the revenue earned for every dollar of assets a company currently reports. Accelerate Diagnostics has an asset utilization ratio of 38.45 percent. This suggests that the Company is making $0.38 for each dollar of assets. An increasing asset utilization means that Accelerate Diagnostics is more efficient with each dollar of assets it utilizes for everyday operations.Accelerate Diagnostics Ownership Allocation
Accelerate Diagnostics holds a total of 25.04 Million outstanding shares. Accelerate Diagnostics retains significant amount of outstanding shares owned by insiders. An insider is usually defined as a CEO, other corporate executive, director, or institutional investor who own at least 10% of the company's outstanding shares. Please note that no matter how many assets the company secures, if the real value of the firm is less than the current market value, you may not be able to make money on it.Accelerate Diagnostics Profitability Analysis
The company reported the previous year's revenue of 12.06 M. Net Loss for the year was (61.62 M) with profit before overhead, payroll, taxes, and interest of 2.89 M.About Accelerate Diagnostics Valuation
Our relative valuation model uses a comparative analysis of Accelerate Diagnostics. We calculate exposure to Accelerate Diagnostics's market risk, different technical and fundamental indicators, and relevant financial multiples and ratios and then compare them to those of Accelerate Diagnostics's related companies.| Last Reported | Projected for Next Year | ||
| Gross Profit | 2.9 M | 1.6 M | |
| Pretax Profit Margin | (5.80) | (6.08) | |
| Operating Profit Margin | (5.15) | (5.41) | |
| Net Loss | (5.88) | (6.17) | |
| Gross Profit Margin | 0.24 | 0.23 |
Accelerate Diagnostics Growth Indicators
Growth stocks usually refer to those companies expected to grow sales and earnings faster than the market average. Growth stocks typically don't pay dividends, often look expensive, and usually trading at a high P/E ratio. Nevertheless, such valuations could be relatively cheap if the company continues to grow, which will drive the share price up. However, since most investors are paying a high price for a growth stock, based on expectations, if those expectations are not fully realized, growth stocks can see dramatic declines.
| Common Stock Shares Outstanding | 12.5 M |
Accelerate Diagnostics Current Valuation Indicators
Valuation refers to the process of determining the present value of Accelerate Diagnostics and all of its assets. It can be calculated using a number of techniques. As many analysts who try to value Accelerate we look at many different elements of the entity such as Accelerate's management, its prospective future earnings, the current market value of the company's assets, as well as its capital structure formation.
Valuations are an essential part of business, for companies themselves, but also for investors. For companies, such as Accelerate Diagnostics, valuations can help measure their progress and success and can help them track their performance in the market compared to others. In addition, investors can use Accelerate Diagnostics' valuations to help determine the worth of potential investments. They can do this by using data and information made public by a company. Regardless of who the valuation is for, it essentially describes Accelerate Diagnostics' worth.Additional Tools for Accelerate Stock Analysis
When running Accelerate Diagnostics' price analysis, check to measure Accelerate Diagnostics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Accelerate Diagnostics is operating at the current time. Most of Accelerate Diagnostics' value examination focuses on studying past and present price action to predict the probability of Accelerate Diagnostics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Accelerate Diagnostics' price. Additionally, you may evaluate how the addition of Accelerate Diagnostics to your portfolios can decrease your overall portfolio volatility.